Clinical Trial Detail

NCT ID NCT04109924
Title TAS-102, Irinotecan, and Bevacizumab for the Treatment of Pre-treated Metastatic or Unresectable Colorectal Cancer, the TABAsCO Study
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Roswell Park Cancer Institute

rectum adenocarcinoma

colon adenocarcinoma


Bevacizumab + Irinotecan + trifluridine/tipiracil hydrochloride

Age Groups: adult senior

No variant requirements are available.